Bolt Biotherapeutics, Inc. (BOLT): Capital Expenditures
$72.0K
Year ended 2025-12-31
$85.0K
Trailing 12 months to 2026-06-30
-66.7%
3-year compound annual growth
-53.4%
5-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $72.0K | +75.6% | 2026-03-12, From 2025-01-01 |
| 2024-12-31 | $41.0K | -80.1% | 2026-03-12, From 2024-01-01 |
| 2023-12-31 | $206.0K | -89.5% | 2025-03-24, From 2023-01-01 |
| 2022-12-31 | $1.95M | -16.5% | 2024-03-21, From 2022-01-01 |
| 2021-12-31 | $2.34M | -28.3% | 2023-03-29, From 2021-01-01 |
| 2020-12-31 | $3.26M | n/a | 2022-03-30, From 2020-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Bolt Biotherapeutics, Inc. (BOLT) | 2025-12-31 | $72.0K | +75.6% |
| Adagene Inc. (ADAG) | 2025-12-31 | $17.1K | -49.2% |
| Aclaris Therapeutics, Inc. (ACRS) | 2025-12-31 | $111.0K | -8.3% |
| Xenon Pharmaceuticals Inc. (XENE) | 2025-12-31 | $799.0K | -74.0% |
| Ovid Therapeutics Inc. (OVID) | 2025-12-31 | $0 | -100.0% |
| Roivant Sciences Ltd. (ROIV) | 2026-03-31 | $8.21M | +78.5% |
| Whitehawk Therapeutics, Inc. (WHWK) | 2025-12-31 | $552.0K | -66.6% |
| Immunome Inc. (IMNM) | 2025-12-31 | $9.69M | +35.0% |
| BioAge Labs, Inc. (BIOA) | 2025-12-31 | $719.0K | +96.4% |
Compare BOLT, ADAG, ACRS, XENE side by side · Screen every company in Pharmaceutical Preparations ↗